DEL in action – selected case studies

How leading pharmaceutical and biotech partners are accelerating early drug discovery with Vipergen’s DEL technology and integrated screening platform.

Get In Touch

1.5B+

Compounds synthesized

12/20

Top global pharma partners

120+

Completed screening projects

+20 yrs

DEL expertise since 2005

In-cell DEL screening delivers hits against a helicase-like polymerase domain not amenable to in vitro selection

CASE STUDY · cBTE PLATFORM · DNA DAMAGE RESPONSE A helicase-like domain of a DNA polymerase implicated in the DNA damage response was screened…

DEL Screening of a Difficult Protease Cancer Target: 11 Confirmed Inhibitors from a Single cBTE Screen

Case Study · cBTE Platform · Oncology Using Cellular Binder Trap Enrichment (cBTE) against a 500-million-compound DNA-encoded library, Vipergen…

First small-molecule modulators of SOX2 — found inside living cells

Case Study · DELS In Cells SOX2 is an oncogenic pioneer transcription factor with no defined binding pocket and, until now, no reported…

Molecular glues for an oncology target — discovered directly in living cells

Using DELs in Cells – Molecular Glue Direct, Vipergen screened an oncology target in triplex with two E3 ubiquitin ligases and identified 89 hits…

Novel inhibitors of an inflammatory kinase – found first try

Using Binder Trap Enrichment screening against a 12.6 million-compound yoctoReactor library, Vipergen identified selective, single-digit nanomolar…

Small molecule drug discovery for even hard-to-drug targets - identify inhibitors, binders and modulators	In living cell In vitro
Molecular Glue Direct	In living cell In vitro
PPI Inhibitor Direct	In living cell In vitro
Integral membrane proteins	In living cell In vitro
Selectivity Direct – multiplexed screening of target and anti-targets	In living cell In vitro
Express - optimized for fast turn-around-time	In living cell In vitro
Snap - easy, fast, and affordable	In living cell In vitro